What will be the next significant regulatory milestone for JYB1904 (RPT904) by December 31, 2025?
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
No significant milestone • 25%
Official announcements from RAPT Therapeutics or regulatory agencies
RAPT Therapeutics Announces $150 Million Private Placement at $0.85/Share, 90.4% Pre-Market Surge, and License Agreement with Shanghai Jemincare
Dec 23, 2024, 01:31 PM
RAPT Therapeutics has announced a $150 million private placement, which includes 176.5 million shares and warrants priced at $0.85 per share. The company also entered an exclusive license agreement with Shanghai Jemincare for its novel long-acting anti-IgE antibody, JYB1904 (RPT904). Under this agreement, RAPT will retain worldwide rights to the drug, excluding mainland China, Hong Kong, Macau, and Taiwan. Jemincare will receive a $35 million upfront payment and could earn up to $672.5 million in milestone payments. Following these announcements, RAPT's stock experienced a significant pre-market increase of 90.4% and was up 74% during trading hours.
View original story
Approved • 33%
Request for more data • 34%
Rejected • 33%
No progress • 25%
Conditional approval • 25%
Phase III trial initiation • 25%
BLA submission • 25%
China • 25%
European Union • 25%
Japan • 25%
Other • 25%
Approve continuation • 25%
Suspend trial • 25%
Request modifications • 25%
No action taken • 25%
One • 25%
Two • 25%
None • 25%
Three or more • 25%
Approval delayed • 25%
Approved • 25%
Rejected • 25%
Other outcome • 25%
Yes • 50%
No • 50%
$1.51 to $2.00 • 25%
Above $2.00 • 25%
Below $1.00 • 25%
$1.00 to $1.50 • 25%